SYNCHRONIZE-1 is the largest published survodutide obesity trial to date. The useful evidence is in the complete denominator, estimand, placebo response and adverse-event pattern—not in a single headline percentage.
What the record shows
- The trial randomized 725 adults with obesity without diabetes.
- At week 76, mean weight change was −12.2% and −13.0% in the two survodutide groups versus −5.4% with placebo.
- Gastrointestinal adverse events occurred in 80.9% and 89.7% of survodutide participants versus 47.9% with placebo.
Study record
The treatment-regimen estimand reported mean changes of −12.2% (95% CI, −13.6 to −10.8) and −13.0% (95% CI, −14.4 to −11.6), compared with −5.4% (95% CI, −6.9 to −4.0) for placebo. Both active comparisons were statistically significant.
Results in context
The ≥5% responder endpoint points in the same direction, but the placebo group also had a substantial response. That matters because all groups participated in a controlled trial rather than a no-intervention comparison.
The paper calls survodutide investigational. It does not establish interchangeability between the trial formulation and an independently sourced catalog material.
What this study cannot answer
The participants did not have diabetes, so the result should not be generalized to every metabolic population.
One phase 3 paper cannot answer questions about long-term post-approval use, rare events, or an unrelated research lot.
Sources & editorial method
The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.
3 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-08-28. Null findings and study limitations are retained. This is not independent peer review, medical advice, a customer case, or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- Survodutide Once Weekly for the Treatment of Adults with Obesityle Roux CW, et al. New England Journal of Medicine. 2026. PMID 42253238 · DOI 10.1056/NEJMoa2600751.
- Survodutide phase 2 obesity trialDose-ranging clinical context; PMID 38330987.
- SYNCHRONIZE-1 trial registryClinicalTrials.gov NCT06066515.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
